Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a phase I study

Anjali Advani, Bertrand Coiffier, Myron S. Czuczman, Martin Dreyling, James Foran, Eva Gine, Christian Gisselbrecht, Nicolas Ketterer, Sunita Nasta, Ama Rohatiner, Ingo G.H. Schmidt-Wolf, Martin Schuler, Jorge Sierra, Mitchell R. Smith, Gregor Verhoef, Jane N. Winter, Joseph Boni, Erik Vandendries, Mark Shapiro, Luis Fayad

Research output: Contribution to journal › Article › peer-review

245 Scopus citations

Fingerprint

Dive into the research topics of 'Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a phase I study'. Together they form a unique fingerprint.

Medicine & Life Sciences